This may be explained by the number of primary, non‐metastatic breast tumor tissue in our sample, as the incidence of ESR1 mutations rises to 15% to 20% in metastatic ER‐positive tumors after prior endocrine treatments, suggesting the development of resistance.32 The gene discussed is ESR1; the disease is breast neoplasm.